Drug Discovery World

SEPTEMBER 9, 2022

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of advanced cancers.

Virus 130

Virus Research Immune Response Engineering 130

Drug Discovery World

AUGUST 7, 2024

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. It is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection.

Drug Trials 147

Drug Trials FDA Trials Immune Response 147

Drug Discovery World

DECEMBER 22, 2022

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. . The post AI identifies drug candidates for respiratory syncytial virus appeared first on Drug Discovery World (DDW).

Virus 130

Virus Clinical Trials Drugs Hospitals 130

ProRelix Research

SEPTEMBER 7, 2023

Autoimmune disorders comprise several diseases in which the immune system mistakenly attacks and destroys the body’s own healthy cells instead of destroying bacteria and viruses to keep the body healthy. […] The post Autoimmune disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.

Clinical Trials 105

Clinical Trials Trials Treatment Virus 105

Drug Discovery World

AUGUST 23, 2022

A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France. . The post Bayer gets go-ahead for Huntington’s Disease gene therapy trial appeared first on Drug Discovery World (DDW).

Therapies 246

Therapies Disease Trials Clinical Trials 246

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus. Official comments .

Clinical Trials 130

Clinical Trials Trials Virus Vaccine 130

Drug Discovery World

JUNE 28, 2023

Biopharmaceutical company InflaRx has launched Gohibic (vilobelimab) in the US for the treatment of Covid-19. Our team is proud to contribute to the fight against this terrible virus with a potentially lifesaving therapeutic option for some of the most critically ill Covid-19 patients.” compared to placebo in the global data set.

Treatment 130

Treatment Virus FDA Trials 130

Drug Discovery World

JULY 12, 2024

Clinical trial news has caught our attention this week. Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease. Mission awarded $5.2m

Clinical Trials 130

Clinical Trials Virus Trials Vaccine 130

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drug Discovery World

AUGUST 2, 2022

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. .

Trials 130

Trials FDA Immune Response Clinical Trials 130

Drug Discovery World

AUGUST 24, 2022

A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments. . The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment.

Research 246

Research Clinical Trials Virus Trials 246

Drug Discovery World

JUNE 28, 2024

This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as the launch of DDW’s latest In Focus report.

Clinical Trials 130

Clinical Trials Drugs Trials Virus 130

Drug Discovery World

APRIL 3, 2023

The findings indicate that a drug compound, R805/CX-011, may modulate an important cell receptor in the body’s immune system, GP130, that signals when antibodies should attack a virus or infection. The post Potentially ‘regenerative’ osteoarthritis drug moves to clinical trial appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Trials FDA Approval Drugs 130

Drug Discovery World

JUNE 28, 2024

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and Europe.

Therapies 147

Therapies Disease Medical Schools Trials 147

Drug Discovery World

AUGUST 9, 2024

Recombinant polyclonal drug trial for HBV gets FDA green light The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339.

FDA 130

FDA FDA Approval Engineering Drugs 130

Drug Discovery World

DECEMBER 18, 2023

The researchers plan to conduct a first-in-human clinical trial in the next five years. For added safety, they used a virus that is unable to replicate to carry the potassium channel gene. Before giving the treatment, researchers monitored the mice’s brain activity for 15 days.

Therapies 264

Therapies Virus Regulations Clinical Trials 264

Drug Discovery World

OCTOBER 9, 2023

Despite the size of the market and the global impact, there are currently no effective treatments. In short, the virus crashes the CPU, and the whole system slows down significantly. DS: As new variants begin circulating, what impact could this finding have on our understanding and the potential treatment of long Covid?

Drug Development 147

Drug Development Clinical Trials Virus Drugs 147

Drug Discovery World

SEPTEMBER 26, 2023

Researchers have uncovered a link between antiviral drug molnupiravir and a pattern of mutations in the SARS-CoV-2 virus. Molnupiravir induces mutations in the virus’s genome during replication, with the aim of damaging or killing the virus.

Virus 130

Virus Clinical Trials Treatment Research 130

Drug Discovery World

JUNE 23, 2023

The Food and Drug Administration (FDA) has granted accelerated approval to Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus (AAV) based gene therapy for the treatment of DMD. The increases in Elevidys dystrophin expression and the functional results that we see can make a difference in the lives of our patients.”

FDA Approval 243

FDA Approval Therapies FDA Protein Expression 243

Advarra

JUNE 13, 2024

Recombinant DNA technologies and genetically modified biological agents are being adapted for a wide scope of therapeutic applications, and their use is becoming increasingly common in clinical trials. The SOP should list these symptoms and any available prophylaxis for post-exposure treatment.

Clinical Trials 52

Clinical Trials Engineering Trials Virus 52

Drug Discovery World

JULY 12, 2024

AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of Parkinson’s disease.

Therapies 147

Therapies Clinical Trials FDA Clinical Development 147

Drug Discovery World

OCTOBER 18, 2023

Sara Donnelly, Director of Research Planning and Business Development at PhoenixBio USA explores why the right pre-clinical model is essential for teams wanting to advance adeno-associated virus vector-based gene therapies. Adeno-associated virus (AAV) vector-based gene therapies hold exceptional promise across a range of disease areas.

Therapies 162

Therapies Clinical Trials FDA Approval Virus 162

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases. News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

The Pharma Data

APRIL 27, 2023

There are no RSV vaccines or specific treatments currently available for older adults. The positive opinion is supported by data from the pivotal AReSVi-006 ( A dult R espiratory S yncytial V irus) phase III vaccine efficacy trial. In the trial, the vaccine candidate showed 82.6% (96.95% CI, 57.9–94.1, Source link: [link]

Virus 40

Virus Vaccine Trials Clinical Trials 40

Drug Discovery World

JUNE 6, 2024

Professor Charles Swanton, Cancer Research UK’s chief clinician, said the melanoma trial results were “extremely impressive”, adding: “The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse. months after initial treatment.

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

JULY 26, 2022

BM: Calidi Therapeutics’ current pipeline consists of oncolytic virus-based immunotherapies potentiated by allogeneic stem cells and designed to treat patients for whom few, if any, effective treatment options exist. RA: How do oncolytic viruses work to attack cancer cells? Both therapies also had excellent safety profiles.

Virus 130

Virus Clinical Trials Therapies Trials 130

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus. Unsubscribe any time.

RNA 93

RNA Virus DNA Vaccine 93

The Pharma Data

JANUARY 27, 2021

COVID-19 Antibody Treatments Exceed Expectations in Early Trials. Instead of an intravenous drip, the drug was given as multiple shots, which will make the treatment easier to deliver, the AP said. All tested negative for the virus but live with someone who has COVID-19. Professional. WEDNESDAY, Jan.

Treatment 52

Treatment Trials Hospitals Virus 52

Drug Discovery World

FEBRUARY 28, 2024

According to the American Association of Cancer Research (AACR) 2 , research-driven advances in treatments have resulted in the decline in death rates for melanoma, leukaemia, and kidney cancer. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

OCTOBER 21, 2022

Amid continued concern about antibiotic resistance, the headline news this week was the discovery of a new antibiotic that could be effective against some of the most treatment-resistant pathogens. . A research team from Boston University has caused controversy for work involving the creation of a hybrid SARS-CoV-2 virus. .

Small Molecule 130

Small Molecule Virus Drugs Clinical Trials 130

Drug Discovery World

JUNE 29, 2023

Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s broad repositories of curated disease data were analysed using CytoReason’s AI-led platform. The analysis has led to the discovery of multiple novel drug targets for the treatment of influenza.

Drugs 245

Drugs Virus Disease Trials 245

The Pharma Data

AUGUST 28, 2020

Celltrion Group has announced that the Korean Ministry of Food and Drug Safety has approved the company’s Investigational New Drug application for a Phase 1 trial for their coronavirus antiviral antibody treatment candidate.

Trials 52

Trials Treatment Clinical Trials Pharmacokinetics 52

Drug Discovery World

FEBRUARY 10, 2023

Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient populations in trials were exposed.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Drug Discovery World

AUGUST 1, 2024

DDW Editor Reece Armstrong speaks to Dr Steven Powell , co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Ultimately, however, clinical trials are needed to confirm efficacy.

Drugs 147

Drugs Clinical Trials Therapies Production 147

The Pharma Data

SEPTEMBER 1, 2020

Sanofi is halting clinical trials treating serious COVID-19 patients with its Kevzara drug after the data proved inconclusive. The Phase 3 trial did not meet the primary or secondary endpoints compared with placebo and established hospital care. Conor Kavanagh. Source link.

Trials 52

Trials Treatment Clinical Trials Vaccine 52

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52

Drug Discovery World

OCTOBER 4, 2022

We found out that Omicron infection protects against flu, studies in potential treatments for severe Covid have shown promise, and new genetic insights into ME and CSF were revealed that could have implications in long Covid. . Researchers successfully exploit virus against advanced cancers .

Virus 130

Virus Engineering Treatment Trials 130